This inventor holds 2 USPTO granted patents. Top assignee: Santen Pharmaceutical Co., Ltd.. Active years: 1998-2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1998-2002
Title: Kiyoshi Matsuno: Innovator in Therapeutic Agents
Introduction
Kiyoshi Matsuno is a notable inventor based in Toyonaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of therapeutic agents for drug dependence. His innovative work has led to the filing of multiple patents, showcasing his expertise and dedication to improving healthcare.
Latest Patents
Kiyoshi Matsuno holds 2 patents, with his latest inventions focusing on therapeutic agents for drug dependence. One of his notable patents describes a method for preventing or treating drug dependence by administering a pharmaceutically effective amount of a 1,4-(diphenylalkyl)piperazine compound. This compound is represented by a specific formula, which includes various lower alkoxy and lower alkylene groups, demonstrating his intricate understanding of chemical compounds and their applications in medicine.
Career Highlights
Matsuno is currently associated with Santen Pharmaceutical Co., Ltd., where he continues to contribute to the advancement of pharmaceutical research and development. His work is characterized by a commitment to finding effective solutions for complex medical issues, particularly in the realm of drug dependence.
Collaborations
Throughout his career, Kiyoshi Matsuno has collaborated with esteemed colleagues such as Yoichi Kawashima and Junzo Matsumoto. These partnerships have fostered a collaborative environment that enhances innovation and drives progress in their shared field of expertise.
Conclusion
Kiyoshi Matsuno's contributions to the pharmaceutical industry, particularly in the area of drug dependence, highlight his role as a significant inventor. His patents and collaborations reflect a commitment to advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
